EUVIMEDEUVIMED entdecken
Übersichtsarbeit

ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension

Evelyn Mendoza-Torres, Alejandra Oyarzún, David Mondaca-Ruff, Andrés Azocar, Pablo F Castro, Jorge E Jalil, Mario Chiong, Sergio Lavandero, María Paz Ocaranza

Therapeutic Advances in Cardiovascular Disease · 2015-08 · 9 (4) · 217-237

DOI: 10.1177/1753944715597623 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 13.08.2015. Verfasst von Evelyn Mendoza-Torres und 8 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Center for Chronic Diseases (ACCDiS), Centro de Estudios Moleculares de la Célula, Facultad de Ciencias Quimicas y Farmaceuticas and Faculta…. Die Arbeit wurde bisher 130-mal zitiert (Crossref) und nennt 205 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The renin–angiotensin system (RAS) is a key component of cardiovascular physiology and homeostasis due to its influence on the regulation of electrolyte balance, blood pressure, vascular tone and cardiovascular remodeling. Deregulation of this system contributes significantly to the pathophysiology of cardiovascular and renal diseases. Numerous studies have generated new perspectives about a noncanonical and protective RAS pathway that counteracts the proliferative and hypertensive effects of the classical angiotensin-converting enzyme (ACE)/angiotensin (Ang) II/angiotensin type 1 receptor (AT1R) axis. The key components of this pathway are ACE2 and its products, Ang-(1-7) and Ang-(1-9). These two vasoactive peptides act through the Mas receptor (MasR) and AT2R, respectively. The ACE2/Ang-(1-7)/MasR and ACE2/Ang-(1-9)/AT2R axes have opposite effects to those of the ACE/Ang II/AT1R axis, such as decreased proliferation and cardiovascular remodeling, increased production of nitric oxide and vasodilation. A novel peptide from the noncanonical pathway, alamandine, was recently identified in rats, mice and humans. This heptapeptide is generated by catalytic action of ACE2 on Ang A or through a decarboxylation reaction on Ang-(1-7). Alamandine produces the same effects as Ang-(1-7), such as vasodilation and prevention of fibrosis, by interacting with Mas-related GPCR, member D (MrgD). In this article, we review the key roles of ACE2 and the vasoactive peptides Ang-(1-7), Ang-(1-9) and alamandine as counter-regulators of the ACE–Ang II axis as well as the biological properties that allow them to regulate blood pressure and cardiovascular and renal remodeling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin IAngiotensin IIAngiotensin-Converting Enzyme 2AnimalsBlood PressureCardiovascular DiseasesHumansHypertensionKidney DiseasesMiceOligopeptidesPeptide FragmentsPeptidyl-Dipeptidase AProto-Oncogene MasRatsRenin-Angiotensin System

Stichwörter der Autor:innen

ACE2alamandineangiotensin-(1-7)angiotensin-(1-9)blood vesselshearthypertensionkidneyrenin–angiotensin systemtissue remodeling

Substanzen

MAS1 protein, humanOligopeptidesPeptide FragmentsProto-Oncogene Masalamandineangiotensin I (1-9)Angiotensin IIAngiotensin IPeptidyl-Dipeptidase AACE2 protein, human

Autor:innen und Institutionen

  • Advanced Center for Chronic Diseases (ACCDiS), Centro de Estudios Moleculares de la Célula, Facultad de Ciencias Quimicas y Farmaceuticas and Facultad de Medicina, Universidad de Chile, Santiago, Chile.
  • Advanced Center for Chronic Diseases (ACCDiS), Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile Division Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Católic…
  • Division Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Advanced Center for Chronic Diseases (ACCDiS), Centro de Estudios Moleculares de la Célula, Facultad de Ciencias Quimicas y Farmaceuticas and Facultad de Medicina, Universidad de Chile, Santiago, Chile Department of Int…
  • Advanced Center for Chronic Diseases(ACCDiS), Facultad de Medicina, PontificiaUniversidad Católica de Chile, Santiago, Chile.Division Enfermedades Cardiovasculares,Facultad de Medicina, Pontificia UniversidadCatólica de…

Zitieren

APA

Mendoza-Torres, E., Oyarzún, A., Mondaca-Ruff, D., Azocar, A., Castro, P. F., Jalil, J. E., Chiong, M., Lavandero, S., & Ocaranza, M. P. (2015). ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Therapeutic Advances in Cardiovascular Disease, 9(4), 217-237. https://doi.org/10.1177/1753944715597623

Vancouver

Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D, Azocar A, Castro PF, Jalil JE, et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Therapeutic Advances in Cardiovascular Disease. 2015;9(4):217-237. doi:10.1177/1753944715597623

BibTeX
@article{MendozaTorres2015,
  author = {Mendoza-Torres, Evelyn and Oyarzún, Alejandra and Mondaca-Ruff, David and Azocar, Andrés and Castro, Pablo F and Jalil, Jorge E and Chiong, Mario and Lavandero, Sergio and Ocaranza, María Paz},
  title = {ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension},
  journal = {Therapeutic Advances in Cardiovascular Disease},
  year = {2015},
  volume = {9},
  number = {4},
  pages = {217--237},
  doi = {10.1177/1753944715597623}
}
Kostenlos starten →